Incyte Corporation (INCY): Price and Financial Metrics


Incyte Corporation (INCY)

Today's Latest Price: $97.62 USD

2.33 (-2.33%)

Updated Aug 5 6:55pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 343 in Biotech

See all "A" rated Strong Buy stocks

INCY Stock Summary

  • Incyte Corp's market capitalization of $21,858,973,546 is ahead of 91.3% of US-listed equities.
  • Of note is the ratio of Incyte Corp's sales and general administrative expense to its total operating expenses; merely 9.36% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Incyte Corp is higher than it is for about just 6.42% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Incyte Corp are LASR, QTWO, CMBM, BLDP, and SSP.
  • INCY's SEC filings can be seen here. And to visit Incyte Corp's official web site, go to www.incyte.com.
INCY Daily Price Range
INCY 52-Week Price Range

INCY Stock Price Chart Technical Analysis Charts


INCY Price/Volume Stats

Current price $97.62 52-week high $110.36
Prev. close $99.95 52-week low $62.48
Day low $96.25 Volume 1,390,000
Day high $101.00 Avg. volume 1,772,067
50-day MA $101.14 Dividend yield N/A
200-day MA $88.72 Market Cap 21.22B

Incyte Corporation (INCY) Company Bio


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.





INCY Latest News Stream


Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream


Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

These five high yield drug stocks pay dividends with attractive yields, and also are undervalued. And as a result, these stocks offer good upside potential to investors. As a group, they are cheap. Yet, they have solid earnings that cover their dividends, plus good growth prospects.I wanted to find these high-yield drug stocks since there is a lot of news out there about pharmaceutical companies that are trying to find a vaccine. I figured some of these larger drug companies can be both innovative and also have a diversified level of income.This helps the pharmaceutical company satisfy the return objectives of its existing investors. However, they also offer enough growth prospects to provide upside potential for new investors.InvestorPlace - Stock Market News, Stock Advice & Trading Ti...

Yahoo | July 24, 2020

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoint

Business Wire | July 23, 2020

Incyte's Jakafi successful in another graft-versus-host disease study (NASDAQ:INCY)

Incyte (NASDAQ:INCY) announces positive results from a Phase 3 clinical trial, REACH3, evaluating Jakafi (ruxolitinib) in patients with moderate or severe

Seeking Alpha | July 23, 2020

Incyte Could Rise Another 15% From Here

Incyte Inc. is in a cutting-edge industry and its shares are poised for an upside breakout. Let's check out the charts for a technical strategy that makes sense. In the daily bar chart of INCY, below, we can see some rapid swings.

Yahoo | July 20, 2020

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 4, 2020. The schedule for the press release and conference call/webcast is as follows: Q2 2020 Press Release: August 4, 2020 at 7:00 a.m. ET Q2 2020 Conference Call: August 4, 2020 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Numb

Business Wire | July 16, 2020

Read More 'INCY' Stories Here

INCY Price Returns

1-mo -10.15%
3-mo 1.77%
6-mo 31.67%
1-year 21.33%
3-year -26.05%
5-year -4.29%
YTD 11.80%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%
2015 48.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8127 seconds.